思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 2025年6月6日，国产心血管龙头企业 先健科技（HKEX：1302） 发布公告称， 其全资子公司先健深圳将向电生理创新企业 剑虎医疗 投资 1.5亿元人民币 ，换取后 者 30%股权 ，并与其签署战略合作协议。 此次投资将分阶段完成，第一阶段将立即交割22.22%股权，其余份额将视里程碑完成情况逐步落实。 除了股权注入，合作协议还赋予先健科技对剑虎医疗电生理产品的独家优先合作权及海外独家经销权，涵盖 三维标测系统、PFA消融平台及多类导管耗材。 双方将 在心脏介入影像平台产品的联合研发与商业化方面展开深度协作，意在构建具备全球竞争力的国产房颤治疗整体解决方案。 # 关于剑虎医疗 剑虎医疗科技（苏州）有限公司 成立于2021年，聚焦新一代心脏电生理成像和能量治疗平台。其核心团队由中国工程院院士陈亚珠领衔、姑苏创业领军人才赵永明 博士创办，技术骨干来自美敦力、强生、西门子等跨国企 ...

Investment Rating - Investment Rating: Buy (Maintained) [1] Core Views - The company reported a revenue of 2.066 billion yuan in 2024, representing a year-on-year increase of 25.18%, and a net profit attributable to shareholders of 673 million yuan, up 26.08% year-on-year [4][5] - In Q1 2025, the company achieved a revenue of 564 million yuan, reflecting a year-on-year growth of 23.93%, and a net profit of 183 million yuan, which is a 30.69% increase year-on-year [4][5] - The company has successfully expanded its electrophysiology business, with over 1,360 hospitals covered and a 50% increase in the number of three-dimensional electrophysiology surgeries performed in 2024 [5][6] Financial Performance - The company’s revenue from coronary access reached 1.054 billion yuan in 2024, a year-on-year increase of 33.30%, while electrophysiology revenue was 440 million yuan, up 19.73% [6] - The company’s overseas revenue was 280 million yuan, showing a growth of 19.75%, with a notable 45.88% increase in international business under its own brand [6] - The projected revenues for 2025, 2026, and 2027 are 2.741 billion yuan, 3.580 billion yuan, and 4.664 billion yuan, respectively, with growth rates of 32.7%, 30.6%, and 30.3% [7][8] Earnings Forecast - The expected net profits for 2025, 2026, and 2027 are 907 million yuan, 1.197 billion yuan, and 1.572 billion yuan, with growth rates of 34.8%, 32.0%, and 31.3% [8][10] - The projected EPS for the same years are 9.34 yuan, 12.33 yuan, and 16.19 yuan, with corresponding P/E ratios of 46x, 35x, and 27x [8][10]